Mineralys Therapeutics (MLYS) News Today $9.24 -0.26 (-2.74%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For HypertensionJanuary 19 at 9:00 PM | seekingalpha.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Boosted by Barclays PLCBarclays PLC lifted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 281.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,218 shares of the company's stock after buying an additional 28,208 shares duriJanuary 18 at 3:11 AM | marketbeat.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells 10,757 Shares of StockJanuary 17 at 6:42 AM | insidertrades.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $97,888.70 in StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 10,757 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $97,888.70. Following the completion of the sale, the chief financial officer now owns 226,097 shares of the company's stock, valued at approximately $2,057,482.70. This trade represents a 4.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.January 16, 2025 | marketbeat.comJon Congleton Sells 18,333 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockJanuary 16, 2025 | insidertrades.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CEO Jon Congleton sold 18,333 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.06, for a total transaction of $166,096.98. Following the sale, the chief executive officer now owns 877,608 shares of the company's stock, valued at $7,951,128.48. This trade represents a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 15, 2025 | marketbeat.comMineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and HypertensionJanuary 10, 2025 | msn.comMineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionJanuary 8, 2025 | finance.yahoo.comMineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6% - Time to Sell?January 8, 2025 | marketbeat.comMineralys Therapeutics Advances Lorundrostat to Phase 2 TrialsJanuary 8, 2025 | tipranks.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 4% - What's Next?Mineralys Therapeutics (NASDAQ:MLYS) Shares Up 4% - Time to Buy?December 27, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Trading Down 4.1% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.1% - Time to Sell?December 26, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Shares Up 3% - Here's WhyMineralys Therapeutics (NASDAQ:MLYS) Shares Up 3% - Still a Buy?December 20, 2024 | marketbeat.comFranklin Resources Inc. Purchases 262,922 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Franklin Resources Inc. raised its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 17.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,745,513 shares of the company's stock aftDecember 20, 2024 | marketbeat.comWellington Management Group LLP Invests $775,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Wellington Management Group LLP bought a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 63,998 shares of the company's stock, valued at approximately $775,000. WellingtoDecember 20, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.8% - Time to Sell?Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 3.8% - Should You Sell?December 18, 2024 | marketbeat.comPolar Asset Management Partners Inc. Purchases Shares of 40,500 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Polar Asset Management Partners Inc. acquired a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 40,500 shares ofDecember 7, 2024 | marketbeat.comCaligan Partners LP Raises Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Caligan Partners LP grew its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 31.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 981,155 shares of the company's stock after buying an addiDecember 1, 2024 | marketbeat.comMineralys Therapeutics Reports Q3 2024 Results and Clinical ProgressNovember 14, 2024 | msn.comHC Wainwright Has Bearish Estimate for MLYS FY2024 EarningsMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Mineralys Therapeutics in a research note issued on Tuesday, November 12th. HC Wainwright analyst M. Caufield now forecasts that the company will earnNovember 14, 2024 | marketbeat.comLifesci Capital Has Pessimistic View of MLYS FY2024 EarningsMineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Research analysts at Lifesci Capital lowered their FY2024 earnings per share (EPS) estimates for Mineralys Therapeutics in a research note issued to investors on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now expects thatNovember 14, 2024 | marketbeat.comBuy Rating on Mineralys Therapeutics Driven by Lorundrostat’s Potential in Hypertension TreatmentNovember 13, 2024 | markets.businessinsider.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comMineralys Therapeutics (NASDAQ:MLYS) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Tuesday.November 12, 2024 | marketbeat.comMineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | seekingalpha.comMineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 11, 2024 | globenewswire.comInsights into Mineralys Therapeutics's Upcoming EarningsNovember 9, 2024 | benzinga.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Insider David Malcom Rodman Sells 25,482 SharesNovember 9, 2024 | insidertrades.comDavid Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 25,482 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total transaction of $382,994.46. Following the transaction, the insider now owns 135,974 shares of the company's stock, valued at approximately $2,043,689.22. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.November 8, 2024 | marketbeat.comMineralys Therapeutics to Announce Third-Quarter 2024 Financial ResultsNovember 7, 2024 | msn.comMineralys Therapeutics Set to Engage with Investors at Key ConferencesNovember 7, 2024 | msn.comMineralys Therapeutics (MLYS) to Release Quarterly Earnings on MondayMineralys Therapeutics (NASDAQ:MLYS) will be releasing earnings after the market closes on Monday, November 11, Zacks reports.November 5, 2024 | marketbeat.comMineralys Therapeutics to Participate in Upcoming Investor ConferencesNovember 5, 2024 | globenewswire.comMineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024November 4, 2024 | globenewswire.comMineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension TrialNovember 1, 2024 | msn.comBuy Recommendation for Mineralys Therapeutics: Promising Clinical Prospects for Lorundrostat in Hypertension TreatmentOctober 31, 2024 | markets.businessinsider.comBuy Rating for Mineralys Therapeutics: Lorundrostat’s Potential in Hypertension TreatmentOctober 31, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Thursday.October 31, 2024 | marketbeat.comMineralys Therapeutics to Host Virtual Event on Hypertension Treatment AdvancesOctober 24, 2024 | msn.comMineralys Therapeutics to host KOL event on uncontrolled, resistant hypertensionOctober 23, 2024 | markets.businessinsider.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 SharesOctober 16, 2024 | insidertrades.comJon Congleton Sells 15,271 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockOctober 16, 2024 | insidertrades.comAdam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the sale, the chief financial officer now directly owns 236,854 shares of the company's stock, valued at $3,214,108.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.October 15, 2024 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Acquired by Nantahala Capital Management LLCNantahala Capital Management LLC lifted its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 60.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 532,506 shares of the company's stock after purchasing an additional 20October 1, 2024 | marketbeat.comDriehaus Capital Management LLC Increases Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Driehaus Capital Management LLC raised its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 40.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 257,371 shares of the company'sSeptember 30, 2024 | marketbeat.comBlue Owl Capital Holdings LP Trims Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)Blue Owl Capital Holdings LP lessened its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 16.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 450,339 shares of the company's stock after selling 90,74September 28, 2024 | marketbeat.comMineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug TrialSeptember 26, 2024 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYSSeptember 25, 2024 | prnewswire.comMineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of HypertensionSeptember 25, 2024 | globenewswire.com Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address MLYS Media Mentions By Week MLYS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLYS News Sentiment▼0.750.44▲Average Medical News Sentiment MLYS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLYS Articles This Week▼82▲MLYS Articles Average Week Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies APGE News Today AMPH News Today TARS News Today IOVA News Today IRON News Today IBRX News Today WVE News Today BLTE News Today GLPG News Today ARQT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLYS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
